Policy | July 07, 2025
Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
The audit has been concluded with no major observations
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
A triple-action Formula for comprehensive respiratory relief
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Subscribe To Our Newsletter & Stay Updated
